Rockville, Dec. 05, 2022 (GLOBE NEWSWIRE) -- As per a new industry analysis by Fact.MR, a market research and competitive intelligence provider, the global bifurcation lesions market is set to be valued at US$ 2.38 billion in 2023 and is predicted to expand at a CAGR of 6% from 2023 to 2033.
A coronary artery constriction known as a bifurcation lesion occurs next to or involves the origin of an important side branch. For interchange and medical research, the very basic Medina classification is used. It is accompanied by a distinct side branch definition, as well as a variety of measurement and imaging techniques that account for the intricacy of the lesions and treatments.
Demand for bifurcation lesion procedures is increasing due to the rising prevalence of coronary artery diseases and cardiovascular disorders. The senior population is more prone to get affected by heart-related disorders. Also, rising demand for minimally-invasive surgeries and rapid advancements in the technologies for the production of gadgets for bifurcation lesions is boosting sales growth.
Download a Free Sample Copy of this Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=7963
North America and Europe are the dominating marketplaces for bifurcation lesions due to the presence of major market players and positive reimbursement policies. The Asia Pacific market is also expected to increase at a high CAGR during the forecast period due to the rising number of coronary artery surgeries.
Key Takeaways from Market Study
- The global market for bifurcation lesions is projected to reach US$ 4.26 billion by 2033.
- Germany’s market is predicted to expand at a CAGR of 4% during the forecast period.
- Demand for bifurcation lesion devices in China is expected to rise at an impressive CAGR of 10% during the forecast period.
- Demand for peripheral vascular procedures is predicted to increase at a high CAGR of 6.5% from 2023 to 2033.
“Ongoing clinical trials for developing cutting-edge bifurcation stenting treatment methods will substantially drive industry growth going forward” says a Fact.MR analyst.
Key Segments of Bifurcation Lesions Industry Research
- By Type :
- One-stent Bifurcation Lesions
- Two-stent Bifurcation Lesions
- By Application :
- Coronary Vascular
- Peripheral Vascular
- By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Get Customization on this Report for Specific Research Solutions - https://www.factmr.com/connectus/sample?flag=RC&rep_id=7963
Winning Strategy
To increase their market share, top companies are focusing on developing technologically sophisticated bifurcation lesion devices and collaborations with others. The technological and functional developments in bifurcation lesion procedures are boosting market growth.
- Cardiovascular Systems Inc. and Chansu Vascular Technologies, LLC established a partnership in February 2021 intending to create peripheral and coronary drug-coated balloons for use in drug-eluting stents.
- Boston Scientific Corporation, a US-based provider of biomedical/biotechnology engineering products used in interventional medical specialities, purchased Devoro Medical, Inc. in September 2021. Boston Scientific will use the WOLF Thrombectomy Platform created by Devoro Medical to work on clot management and marketing.
- The FDA approved the ultrathin, bioresorbable Orsiro drug-eluting stent made by Biotronik in February 2019. The product is indicated for use during percutaneous coronary intervention (PCI) operations. The company was able to expand its product variety and grow its customer base due to this new launch strategy.
Key Companies Profiled
- Abbott
- Boston Scientific Corporation
- C. R. Bard, Inc.
- Cardinal Health
- Johnson& Johnson Services, Inc.
- Medtronic
- Spectranetics
- Terumo Medical Corporation
Explore Our Safe & Secure Payment Options for Quick Buy – https://www.factmr.com/checkout/7963
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global bifurcation lesions market, presenting historical demand data (2018-2022) and forecast statistics for the period of 2023-2033.
The study divulges essential insights on the market on the basis of type (one-stent bifurcation lesions, two-stent bifurcation lesions) and application (coronary vascular, peripheral vascular), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).
Check out more related studies published by Fact.MR Research:
Gastrointestinal Stents Market: The global gastrointestinal stents market is expected to increase at a CAGR of 5.5% from 2022 to 2027 and climb from a market valuation of US$ 516 million in 2022 to US$ 674.3 million by 2027. Biliary stent sales are predicted to increase faster at a CAGR of 6% and reach a valuation of US$ 313 million by 2027.
Coronary Stents Market: Global sales of coronary stents were valued at around US$ 10.1 Bn in 2020. The global coronary stents market is projected to register 12.9% CAGR and reach a valuation of US$ 25.7 Bn by the end of 2028. Increasing consumption of drug eluting stents, which contribute around 80% share to the overall market size, is significantly driving market expansion.
Venous Stents Market: Global demand for venous stent devices is valued at US$ 1.08 billion in 2022. The market for venous stents is predicted to increase rapidly at a CAGR of 8.5% during the forecast period and reach a market valuation of US$ 2.44 billion by the year 2032.
Esophageal Stents Market: The global esophageal stents market is forecasted to increase at a CAGR of 5.6% from 2022 to 2027. Currently, the market is valued at US$ 80 million and is predicted to reach US$ 105 million by the end of 2027.
Cox 2 Inhibitors Market: Cox 2 Inhibitors are a type of non-steroidal anti-inflammatory drugs. These drugs are responsible for decreasing the production of prostaglandins. These drugs also reduce the production of chemicals that play an important role in promoting fever, inflammatory pain etc. Cyclooxygenase (Cox) is an enzyme, which is responsible for producing prostaglandins.
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Tel: +1 (628) 251-1583
